New marine molecules with therapy potential against Alzheimer's disease

May 28, 2020

An interdisciplinary research study of the University of Barcelona identified two potential candidates to treat Alzheimer's disease. These are two marine molecules, meridianine and lignarenone B, able to alter the activity of GSK3B activity, a protein associated with several neurodegenerative diseases.

The researchers used several biocomputational techniques to detect these so far unknown compounds, which were later validated with experiments in cultures of neuronal cells in mice. These results will allow researchers to better understand the functioning of the GSK3B molecule and build a promising starting point for the development of new drugs against Alzheimer's disease.

The paper, published in the journal Biomolecules, is the result of the collaboration between two UB research teams with the participation of Laura Llorach Pares and Conxita Àvila, from the Faculty of Biology and the Biodiversity Research Institute (IRBio) of the UB, and Ened Rodríguez, Albert Giralt and Jordi Alberch, from the Faculty of Medicine and Health Sciences and the Institute of Neurosciences of the UB (UBNeuro). Other participants were the technological company Molomics and the former company Mind the Byte.

A promising but delicate therapeutic target

The GSK3B is an abundant protein in the brain with an important role in the development of Alzheimer's disease and other neurodegenerative diseases, since changes in their activity affect negatively the basic synaptic signals in learning and memory and these can even be interrupted. This is why, over the last years, researchers made many efforts to design GSK3B inhibitors, although without enough results so far. "GSK3B has always been an appreciated molecule in the treatment for Alzheimer's disease. However, clinical trials with all potential inhibitors caused adverse effects, which were a disappointment. We are still far from any clinical application, the molecules we described have the potential to overcome the limitations of other inhibiting drugs", says Albert Giralt, also member of IDIBAPS and the Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED).

Using biocomputing and molecular dynamic simulation techniques, researchers analysed the potential of a group of marine molecular families -isolated and characterized by the team of Conchita Avila- to inhibit the GSK3B activity. "These are meridianins, a family of alkaloids from marine benthic organisms from the Antartica, and lignarenones, obtained from a gastropod mollusc from the waters of the Mediterranean Sea", notes Àvila.

Impact on neuronal plasticity

Then, the researchers carried out an in vitro experimental validation on the inhibiting ability of these molecules using cultures of mice neurons. The results show both marine compounds do not cause neurotoxic effects and, in addition, they promote structural neuronal plasticity. "The new molecules do not have an excessive inhibition of GSK3B, which is interesting, since inhibiting it excessively could be the cause of some of the adverse effects described for other inhibitor drugs. Also, these induce the growth of the neuronal tree, an aspect of great interest in Alzheimer's disease, where atrophy and dysfunction play a more relevant role in the appearance of symptoms than in neuronal death", notes Albert Giralt.

According to the researchers, this is a relevant discovery, since it is not easy to find new molecules that can be therapeutic for Alzheimer's, specially when many therapeutic targets have been disappointing. However, Giralt says this is only the beginning: "To confirm the potential of these new molecules, the next step is to evaluate during the next years whether treatment with these drugs improves symptomatology in mice models with Alzheimer's, and if so, to try to conduct clinical studies with these molecules", concludes the researcher.

University of Barcelona

Related Neurodegenerative Diseases Articles from Brightsurf:

Bringing drugs to the brain with nanoparticles to treat neurodegenerative diseases
Researchers from the Institut national de la recherche scientifique (INRS) have shown that nanoparticles could be used to deliver drugs to the brain to treat neurodegenerative diseases.

First 'pathoconnectome' could point toward new treatments for neurodegenerative diseases
Scientists from the John A. Moran Eye Center at the University of Utah have achieved another first in the field of connectomics, which studies the synaptic connections between neurons.

Unlocking the mystery of tau for treatment of neurodegenerative diseases
A team of researchers from various collaborating universities and hospitals in Japan has uncovered crucial molecular details regarding the activity of the ''tau'' protein, promising to revolutionize the therapy of tau-induced neurodegenerative diseases.

Investigational drug stops toxic proteins tied to neurodegenerative diseases
An investigational drug that targets an instigator of the TDP-43 protein, a well-known hallmark of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), may reduce the protein's buildup and neurological decline associated with these disorders, suggests a pre-clinical study from researchers at Penn Medicine and Mayo Clinic.

Inhibition of sphingolipid metabolism and neurodegenerative diseases
Disrupting the production of a class of lipids known as sphingolipids in neurons improved symptoms of neurodegeneration and increased survival in a mouse model.

How understanding the dynamics of yeast prions can shed light on neurodegenerative diseases
How understanding the dynamics of yeast prions can shed light on neurodegenerative diseases

New family of molecules to join altered receptors in neurodegenerative diseases
An article published in the Journal of Medicinal Chemistry shows a new family of molecules with high affinity to join imidazoline receptors, which are altered in the brain of those patients with neurodegenerative diseases such as Alzheimer's, Parkinson's and Huntington's.

Examining diagnoses of stress-related disorders, risk of neurodegenerative diseases
Researchers investigated how stress-related disorders (such as posttraumatic stress disorder, adjustment disorder and stress reactions) were associated with risk for neurodegenerative diseases, including Alzheimer and Parkinson disease and amyotrophic lateral sclerosis (ALS), using data from national health registers in Sweden.

Toxic protein, linked to Alzheimer's and neurodegenerative diseases, exposed in new detail
The protein tau has long been implicated in Alzheimer's and a host of other debilitating brain diseases.

Study uncovers unexpected connection between gliomas, neurodegenerative diseases
New basic science and clinical research identifies TAU, the same protein studied in the development of Alzheimer's, as a biomarker for glioma development.

Read More: Neurodegenerative Diseases News and Neurodegenerative Diseases Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to